The anticonvulsant drug carbamazepine (CBZ) is known to exert antimanic and prophylactic effects in the treatment of manic-depressive disorders that are clinically equivalent to the well-known properties of lithium salts. CBZ may even have advantages as compared to lithium in the treatment and prophylaxis of schizoaffective and rapid cycling bipolar disorders (for review see Solomon et al. 1995) . Among the various pharmacological effects of CBZ, its activity as a specific antagonist at adenosine A 1 receptors (van Calker et al. 1991; Biber et al., 1996) may be particularly important, because this property could lead to alterations in the responsiveness of signal transduction systems in the brain (van Calker et al. 1998 ), a mechanism believed to be instrumental also to lithium's beneficial effects in affective disorders (for review see Manji et al. 1995) .
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Adenosine A 1 -and A 2 -receptor subtypes were originally distinguished by their differential effects on adenylyl cyclase (van Calker et al. 1978 (van Calker et al. , 1979 , but more recent findings have revealed coupling of adenosine receptors to other signal transduction systems including phospholipase C (PLC) (Miller and Hoffman 1994; Fredholm et al. 1994) . Very often, the coupling of adenosine A 1 -receptors to PLC ␤ is synergistic with the stim-ulation evoked by other receptors, such as ␣ 1 -adrenergic receptors (El-Etr et al. 1989; Biber et al. 1996 Biber et al. , 1997 , histamine H 1 -receptors (Dickenson and Hill 1994) , muscarinic receptors (Biden and Browne 1993) , or thyrotropin receptors (Okajima et al. 1995) . There are, however, also reports suggesting direct activation of PLC by adenosine A 1 -receptors (Freund et al. 1994; Murthy and Makhlouf 1995) .
We recently reported that the stimulatory effects of adenosine A 1 -receptors on PLC signaling in primary astrocytes from different brain regions depend upon the expression level of adenosine A 1 -receptor mRNA and protein. Adenosine A 1 -receptor mediated PLC activation was only evident in cultures expressing high receptor numbers but was absent in cultures expressing low numbers of adenosine A 1 -receptors (Biber et al. 1997) . We, therefore, hypothesized that upregulation of A 1 -receptors should alter their coupling to second messenger systems. Little is known about the physiological regulation of adenosine A 1 -receptor expression, but available evidence indicates an upregulation of receptor number after chronic treatment with receptor antagonists (Shi et al. 1993; Von Lubitz et al. 1994b ). Thus, chronic treatment (3 weeks) with the antagonist CBZ, also results in upregulation of A 1 -receptors in the brain (Daval et al. 1989) . We report here that in cultured astrocytes with low basal expression of A 1 -receptors mRNA, upregulation of receptor mRNA by CBZ treatment for 10 days induces their coupling to PLC; whereas, mRNA expression and signal transduction of adenosine A 1 -receptors in cultures with high basal mRNA levels remains unaltered.
MATERIALS AND METHODS

Materials
Reagents were purchased from the following sources: cyclopentyladenosine (CPA), phenylephrine (PE), 
Cell Cultures
Astrocyte cultures were established as described previously (Gebicke-Härter et al. 1989) . In brief, rat brains were dissected out of newborn Wistar rat pups ( Ͻ 1d) under sterile conditions, and various brain regions (cortex, hippocampus, striatum, tegmentum, thalamus, and cerebellum) were isolated. Brain tissues were gently dissociated by trituration in Dulbecco's phosphate buffered saline and filtered through a cell strainer (70 m Ø, Falcon) into Dulbecco's modified Eagle's medium (DMEM). After two washing steps (200 ϫ g for 10 min), cells were seeded into 24-well-dishes (Falcon) (5 ϫ 10 5 cells/well). For total RNA and mRNA preparations, cells were grown in 6-well dishes (Falcon) (2 ϫ 10 6 cells/dish) and standard dishes (Falcon, 10 cm Ø) (8 ϫ 10 8 cells/ dish), respectively. Cultures were maintained for 4 weeks in DMEM containing 10% fetal calf serum with 0.01% penicillin and 0.01% streptomycin in a humidified atmosphere (5% CO 2 ) at 37 Њ C. Culture medium was changed on the 2nd day after preparation and every 6 days thereafter.
Cyclic AMP-Determination
Four-week-old cultures were washed three times with 500 l incubation buffer (118 mm NaCl, 4.7 mm KCl, 3 mm CaCl, 1.2 mm MgSO 4 , 1.2 mm KH 2 PO 4 , 0.5 mm EDTA, 10 mm glucose, and 20 mm HEPES; pH 7.4). Cells were then stimulated at 37 Њ C in the same buffer with the ␤ -adrenergic receptor agonist isoproterenol (1 m) in the presence or absence of CPA. After 10 min, the buffer was removed, and the reaction was stopped by addition of 400 l ice-cold ethanol (70%). Dishes were incubated on ice for 30 min, and the supernatants were harvested. 10 l of each sample was dried in a speed vac centrifuge (Bachhofer, Reutlingen, Germany) and redissolved in 500 l sample buffer (cAMP-RIA Kit IBL). Cyclic AMP levels were determined according to the manufacturer's protocol.
Inositolphosphate Determination
Four-week-old cultures were labeled for 24 h with 1 Ci [ 3 H]-myo -inositol in 250 l of culture medium. After three washings with 500 l incubation buffer, cells were incubated for 15 min at 37 Њ C in the same buffer supplemented with 10 mm LiCl and stimulated for 20 min with the ␣ 1 -adrenergic receptor agonist phenylephrine (100 m) in the presence or absence of CPA. The reaction was stopped by addition of ice-cold TCA (100% w/ v) up to a final concentration of 10% TCA. Dishes were incubated on ice for 30 min. Separation of inositolphos-phates was performed on Dowex anion exchange columns (Formiate Form AG 1 ϫ 8) as described previously (van Calker et al. 1987) . In brief, TCA was extracted with diethylether (three times), and samples were neutralized to pH 7 with 5 mm disodium tetraborate. Samples were loaded on Dowex columns, and after two washing steps (10 ml water, 10 ml 50 mm disodium tetraborate/60 mm ammonium formate), inositolphosphates were eluted with 2 ml of 1 m ammonium formate and 0.1 m formic acid. Samples were mixed with 6 ml of liquid scintillation fluid and counted. Determinations were performed in triplicate.
Total RNA Extraction
Cells were lysed in guanidinium isothiocyanate/mercaptoethanol (GTC) solution (250 l/well). Two samples were pooled to a final volume of 500 l lysate and total RNA was extracted according to Chomczynski and Sacchi (1987) .
Cloning of the cDNA Probe for Adenosine A 1 Receptors
Total RNA was reverse transcribed and PCR experiments were carried out as described previously (Biber et al. 1997) . Sequences of oligonucleotide primer pairs and PCR conditions: Adenosine A 1 -receptor, # 55 5 ϽϽ -ATT-GCCTTGGTCTCTGTGC and #690 5 ϽϽ -CAGCTCCT-TCCCGTAGTAC, annealing temperature 59 Њ C, 35 cycles. The PCR product was cloned using the TA cloning kit (Invitrogen) and sequenced by ALF (Pharmacia Biotech, Germany) revealing 100% homology to the known cDNA sequence for rat A 1 -receptor (Mahan et al. 1991) . 50 g of the vector containing the A 1 receptor cDNA was digested by Bst E II, and the fragments were separated on a preparative agarose gel. The 300 bp fragment of the A 1 -receptor cDNA was used for Northern analysis.
mRNA Extraction and Northern Analysis
Cells were lysed in 500 l lysis/binding buffer (Dynal), and mRNA was extracted with 150 l Dynabeads according to the manufacturers protocol. mRNA (2-3 g) was eluted in 15 l water, separated by agarose-formaldehyde gel electrophoresis, blotted onto positively charged nylon membranes (Pharmacia, Freiburg), and cross-linked by exposure to 120 Њ C for 30 min. As a marker 15 g of total RNA was run on the same gel and stained with ethidium bromide to determine the bands for 18 s and 28 s ribosomal RNA. The filters were prehybridized in 50% formamide, 0.25 m Na-phosphate buffer, pH 7.2, 0.25 m NaCl, 10 mm EDTA, 200 g/ml salmon sperm DNA and 7% SDS at 43 Њ C for 2 h. cDNA probes were labeled with 50 Ci [ 32 P]dCTP (Amersham & Buchler, Braunschweig, Germany) using a random priming kit from Stratagene (Heidelberg, Germany). Unincorporated nucleotides were removed using a nucleotide removal kit from Qiagen. Overnight hybridization was performed at 43 Њ C, adding the radiolabeled probe to the prehybridization buffer. Membranes were washed in 2 ϫ SSC/0.1% SDS (3 ϫ 20 min) at 60 Њ C and exposed to Kodak XAR film at Ϫ 80 Њ C for adequate periods of time. For rehybridization, probes were removed by boiling the filter at 95 Њ C in distilled water. Experiments were carried out in triplicate.
RESULTS
Primary astrocyte cultures from different regions of the rat brain were treated for 10 days with CBZ (50 m). Then cultures were analyzed for (1) expression of adenosine A 1 -receptor mRNA (2) adenosine A 1 -receptor mediated inhibition of cyclic AMP synthesis; (3) adenosine A 1 -receptor-mediated potentiation of PLC activation.
Expression of Adenosine A 1 -Receptor mRNA
Adenosine A 1 -receptor mRNA expression was investigated by Northern blot analysis. The results obtained for untreated cultures were similar to those previously obtained by semiquantitative RT-PCR experiments (Biber et al. 1997) . Signals for adenosine A 1 -receptor mRNA were found in mRNA preparations from astrocytes cultured from all brain regions investigated. Higher levels were observed in hippocampal, cortical, tegmental, and thalamic cultures (as shown in Figure  1A for hippocampal cultures); whereas, lower levels were found in cultures from whole brain, striatum, and cerebellum (as shown for cultures from cerebellum in Figure 1B ). Remarkably, treatment with CBZ did not substantially alter the adenosine A 1 -receptor mRNA level in cultures with high expression levels (hippocampus, cortex, thalamus, and tegmentum) ( Figure 1A ). However, a pronounced upregulation of adenosine A 1 -receptor mRNA was observed after CBZ treatment in cultures from whole brain, striatum, and cerebellum ( Figure 1B ).
Inhibition of Cyclic AMP
As already reported, stimulation of adenosine A 1 -receptors leads to inhibition of the isoproterenol-induced increase of cyclic AMP (van Calker et al. 1978) . The maximal inhibitory effect was approximately 50% and independent of the brain region from which the astrocytes had been cultured (Biber et al. 1997 ). Ten-day treatment with the A 1 -receptor antagonist CBZ did not alter these inhibitory effects. No significant changes of the concentration response curves after carbamazepine treatment were observed in cultures with high or with low A 1 mRNA expression (as shown in Figure 2 for cultures from hippocampus and cerebellum, respectively).
Potentiation of PLC-Activation
Astrocyte cultures established from thalamus, tegmentum, cortex, and hippocampus, expressing high levels of adenosine A 1 -receptors, exhibit adenosine A 1 -receptor-mediated potentiation of agonist-activation of PLC (Biber et al. 1997 ). Ten-day treatment of these cultures with CBZ did not significantly influence the signaling of adenosine A 1 -receptors to PLC (Figure 3) . As shown previously, astrocyte cultures established from whole brain, cerebellum, and striatum show only moderate (whole brain) or little, if any, effect of adenosine A 1 -receptor stimulation on PLC activity (Biber et al. 1997 ). Tenday treatment with CBZ, however, significantly increased the adenosine A 1 -receptor-mediated potentiation of PLC activity in cultures from whole brain (Figure 4) and induced an adenosine A 1 -receptor-mediated potentiation in cultures from striatum and cerebellum (Figure 4 ).
DISCUSSION
The results of the present study provide evidence that upregulation of adenosine A 1 -receptors can alter their coupling to signal transduction systems. This is concluded from the following findings.
Primary astrocyte cultures from different brain regions can be subdivided into two groups according to the expression levels of adenosine A 1 -receptor mRNA: those with high expression (cultures from hippocampus, cortex, thalamus, and tegmentum) and those with low (cerebellum, striatum) expression of A 1 -receptor mRNA. Both determination of mRNA by Northern blot analysis (this paper) and with RT-PCR (Biber et al. 1997 ) revealed similar results.
Ten-day treatment with 50 m CBZ (which displays the same A 1 antagonistic activity as 100 nm DPCPX [Biber et al. 1996] ) induced a pronounced upregulation of A 1 -receptor mRNA only in cultures with low expression (cerebellum, striatum, and whole brain). This upregulation of A 1 -receptor mRNA was accompanied by an induction (cerebellum and striatum) or upregulation (whole brain) of adenosine A 1 -receptor-mediated potentiation of PLC activation. On the other hand, CBZ treatment had no effect on mRNA expression and A 1 -receptor signaling in cultures, which already at basal conditions exhibited a high A 1 -receptor mRNA content and an A 1 -receptor-dependent PLC potentiation.
We have shown previously that in these cultures, A 1 -receptor mRNA concentration strictly correlates with receptor-binding properties. Thus, we detected in high expression cultures (hippocampus, cortex, thalamus, and tegmentum) B max values of 24 Ϯ 7 fmol/mg and in low expression cultures (striatum and cerebellum) B max values of р 5 fmol/mg (which was near the detection limit) (Biber et al. 1997) . We verified in one experiment that, after CBZ treatment, not only adenosine A 1 -receptor mRNA is upregulated but also the receptor protein in striatal and cerebellar cultures as determined by radioligand-binding studies. Thus, CBZ treatment induced an increase of B max values up to those observed in the high-affinity group. Therefore, potentiation of PLC activation by A 1 -receptors relies on the number of A 1 -receptors occupied by agonists. This is most likely explained by the bifurcating nature of G-protein signaling; that is, that the activation of one Gi/o protein by one adenosine A 1 -receptor gives rise to two different signal transducers (␣ and ␤␥ subunits) with different affinities for their target enzyme. It is well known that ␣ subunits have 10 to 100-fold higher affinities to their target enzymes than ␤␥ subunits (for review see Müller and Lohse 1995) . The high affinity of ␣ subunits for adenylyl cyclase allows an inhibition already at comparably low numbers of ␣ subunits being activated in cultures with low A 1 -receptor mRNA and protein. In contrast, because of their low affinity to PLC, more free ␤␥ subunits are required to activate PLC, which are released in cultures with high A 1 -receptor expression (Biber et al. 1997) . The results presented here support this notion, because upregulation of A 1 -receptor mRNA upregulates or even induces an A 1 -receptor mediated PLC activation but leaves unaltered the inhibition of adenylyl cyclase by A 1 -receptors.
Several other mechanisms could be envisaged to explain the CBZ-induced increase in the extent of PLCactivation; for example, changes in G-protein content, induction of specific G-protein subunits, changes in levels of PLC, or changes in inositol phospholipid availability. However, we have shown previously that G-protein and PLC contents of all cultures are comparable (measured by a direct activation of Gi/o-proteins by mastoparan) (Biber et al. 1997) . Moreover, there are no data available at the moment indicating that CBZ might have any effect on G-protein and/or PLC activity or expression or inositol phospholipid metabolism.
Adenosine A 1 -receptor up and down regulation by chronic treatment with adenosine A 1 -receptor antagonists and agonists, respectively, has been reported to modulate cerebral ischemia, seizures, spatial learning, and memory (Von Lubitz et al. 1993a ,b, 1994a , but little is known about the physiological consequences of adenosine A 1 -receptor upregulation for their coupling to signal transduction systems. In general, there are only few reports in the literature that examine the consequences of changes in receptor expression for their signal transduction. Upregulation of receptor number may result in an increased signal transduction, as shown for the adenosine A 1 -receptor-mediated inhibition of adenylyl cyclase in chick atrial myocytes (Liang and Hirsch 1993) or the stimulation of adenylyl cyclase by vasoactive intestinal peptide receptors in leukocytes (Wiik 1991) . Other reports, however, indicate that receptor upregulation did not enhance signal transduction events, as shown for bradykinin receptor 2 in human glomerular podocytes (Costenbader et al. 1997) or muscarinic acetylcholin receptors in esophageal sphincter muscle (Keshavarzian et al. 1992 ). To our knowledge, this is the first report indicating that upregulation of a receptor induces a new quality of signal transduction.
Several treatments of affective disorders (CBZ treatment, sleep deprivation, and electroconvulsive therapy [ECT]) lead to an upregulation of adenosine A 1 -receptors in brain (for review see Durcan and Morgan 1990; Williams 1995) . Our results indicate that this upregulation may lead to an increase or induction of Gi/o protein ␤␥ subunit-mediated actions. G protein ␤␥ subunits are known to have several intracellular effects (for review see Müller and Lohse 1995) . Particularly, it is becoming obvious that ␤␥ subunits modify currents through several ion channels in the brain (Ma et al. 1997; Qin et al. 1997; Herlitze et al. 1996; Ikeda 1996; Wickman et al. 1994) . It is, therefore, tempting to speculate that upregulation of adenosine A 1 -receptors in brain during the treatment of affective disorders may influence neuronal excitability by means of an increased or induced ␤␥ subunit-mediated influence on neuronal ion fluxes and that this effect on neuronal activity may participate in the therapeutic effects of CBZ, sleep deprivation, or ECT.
In conclusion, we have provided evidence that a 10-day treatment with CBZ upregulates A 1 -receptor mRNA expression in primary astrocyte cultures from brain regions where receptor expression is low; whereas, receptor mRNA expression in cultures from brain regions where receptor expression is high were unaffected. Upregulation of adenosine A 1 -receptors had no influence on their inhibitory effect on cyclic AMP synthesis but increased or even induced adenosine A 1 -receptor-mediated potentiation of PLC activity. These results support the hypothesis that the coupling of adenosine A 1 -receptors to PLC is determined by their expression level in the cell. They provoke the question as to whether the well-known alterations in the sensivity of receptors for neurotransmitters that are induced by various pharmacological and nonpharmacological ther- 
